DXC vs. MEDP, HQY, BILI, WPP, LYFT, ETSY, AMTM, MARA, WSC, and SEZL
Should you be buying DXC Technology stock or one of its competitors? The main competitors of DXC Technology include Medpace (MEDP), HealthEquity (HQY), Bilibili (BILI), WPP (WPP), Lyft (LYFT), Etsy (ETSY), Amentum (AMTM), Marathon Digital (MARA), WillScot (WSC), and Sezzle (SEZL). These companies are all part of the "business services" industry.
DXC Technology vs. Its Competitors
Medpace (NASDAQ:MEDP) and DXC Technology (NYSE:DXC) are both mid-cap business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.
Medpace has higher earnings, but lower revenue than DXC Technology. DXC Technology is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
78.0% of Medpace shares are owned by institutional investors. Comparatively, 96.2% of DXC Technology shares are owned by institutional investors. 20.3% of Medpace shares are owned by insiders. Comparatively, 0.6% of DXC Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Medpace has a net margin of 19.31% compared to DXC Technology's net margin of 3.02%. Medpace's return on equity of 54.36% beat DXC Technology's return on equity.
Medpace presently has a consensus price target of $344.82, indicating a potential upside of 7.25%. DXC Technology has a consensus price target of $17.00, indicating a potential upside of 4.68%. Given Medpace's stronger consensus rating and higher probable upside, research analysts clearly believe Medpace is more favorable than DXC Technology.
In the previous week, Medpace had 3 more articles in the media than DXC Technology. MarketBeat recorded 8 mentions for Medpace and 5 mentions for DXC Technology. Medpace's average media sentiment score of 0.70 beat DXC Technology's score of 0.25 indicating that Medpace is being referred to more favorably in the media.
Medpace has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, DXC Technology has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.
Summary
Medpace beats DXC Technology on 14 of the 16 factors compared between the two stocks.
Get DXC Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DXC Technology Competitors List
Related Companies and Tools
This page (NYSE:DXC) was last updated on 7/4/2025 by MarketBeat.com Staff
Free DXC Stock Alerts